Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

EDX Medical

EDX Medical launches TC100, UK’s most advanced testicular cancer testing service

EDX Medical Group plc has commenced marketing its TC100 testicular cancer testing service, described as the most advanced of its kind in the UK...
Physicians Capital

When physicians turn practice into property

Physicians are increasingly turning to medical real estate to convert income into lasting ownership, transforming their practices into legacy assets that outlive their careers...
Cizzle Bio

Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)

Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
GSK Plc

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis...
Cizzle Biotechnology Holdings

Cizzle Biotechnology expands North American rollout of CIZ1B lung cancer test

Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Aptamer Group

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event...
Halma plc

Halma Plc lifts FY revenue growth guidance in trading update

Halma plc reported strong progress in the first half of its financial year to 30 September 2025, raising full-year revenue growth guidance to low double-digit organic constant currency growth, up from upper single digits...
Nuformix plc

Nuformix to present NXP002 data at ERS Congress 2025

Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
AstraZeneca

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...
Roquefort Therapeutics

Roquefort Therapeutics Stephen West analyses value of US acquisition (LON:ROQ)

Roquefort Therapeutics Executive Chairman Stephen West discusses the company’s proposed £30 million reverse takeover of Coiled Therapeutics. The deal, supported by a £6 million investment from A2A Pharmaceuticals and its investors, will pivot Roquefort into a clinical-stage biotech, adding AO-252, a novel TACC3-targeting cancer therapy already in Phase I trials, to its pipeline...
One Health Group

One Health Group reports strong trading and progress on surgical hub development

One Health Group has confirmed that trading for the year to date remains in line with expectations, with continued organic growth and progress on its first Surgical Hub in Scunthorpe. The company will provide a further trading update for the six months to 30 September 2025 in late October...

Roquefort Therapeutics secures exclusivity with Coiled Therapeutics RTO, eyeing AIM relist and NASDAQ (Video)

Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
Aptamer

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform...
One Health Group

One Health Group shortlisted for two prestigious awards at the 30th anniversary AIM Awards

Sheffield-headquartered One Health Group plc (LON:OHGR), an independent provider of NHS-funded medical procedures, is delighted to announce that it has been shortlisted for two categories..
Roquefort Therapeutics

Roquefort Therapeutics plc plans transformational acquisition into clinical stage biotech company (LON:ROQ)

Roquefort Therapeutics has signed Heads of Terms to acquire 100% of Coiled Therapeutics, Inc. in a reverse takeover valued at £30 million, payable in shares. Coiled USA, a spin-out from A2A Pharmaceuticals, holds exclusive worldwide rights to AO-252, a first-in-class cancer therapy currently in Phase I trials in the United States...
Physicians Capital

Physicians turning professional insight into real estate advantage

Doctors are using their unique knowledge of healthcare operations to transform medical real estate into a source of stability and long-term independence...
Hutchmed

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...
Genus plc

Genus accelerates China joint venture with BCA to advance PRRS resistant pig

Genus plc has agreed updated terms with Beijing Capital Agribusiness to fast-track the formation of a porcine joint venture in China. The deal secures a US$160m cash payment, milestone income, and future royalties, while positioning PIC China to commercialise PRRS resistant pigs with stronger local backing...
Aptamer Group

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

EDX Medical

EDX Medical launches TC100, UK’s most advanced testicular cancer testing service

EDX Medical Group plc has commenced marketing its TC100 testicular cancer testing service, described as the most advanced of its kind in the UK...
Physicians Capital

When physicians turn practice into property

Physicians are increasingly turning to medical real estate to convert income into lasting ownership, transforming their practices into legacy assets that outlive their careers...
Cizzle Bio

Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)

Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
GSK Plc

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis...
Cizzle Biotechnology Holdings

Cizzle Biotechnology expands North American rollout of CIZ1B lung cancer test

Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Aptamer Group

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event...
Halma plc

Halma Plc lifts FY revenue growth guidance in trading update

Halma plc reported strong progress in the first half of its financial year to 30 September 2025, raising full-year revenue growth guidance to low double-digit organic constant currency growth, up from upper single digits...
Nuformix plc

Nuformix to present NXP002 data at ERS Congress 2025

Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
AstraZeneca

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...
Roquefort Therapeutics

Roquefort Therapeutics Stephen West analyses value of US acquisition (LON:ROQ)

Roquefort Therapeutics Executive Chairman Stephen West discusses the company’s proposed £30 million reverse takeover of Coiled Therapeutics. The deal, supported by a £6 million investment from A2A Pharmaceuticals and its investors, will pivot Roquefort into a clinical-stage biotech, adding AO-252, a novel TACC3-targeting cancer therapy already in Phase I trials, to its pipeline...
One Health Group

One Health Group reports strong trading and progress on surgical hub development

One Health Group has confirmed that trading for the year to date remains in line with expectations, with continued organic growth and progress on its first Surgical Hub in Scunthorpe. The company will provide a further trading update for the six months to 30 September 2025 in late October...

Roquefort Therapeutics secures exclusivity with Coiled Therapeutics RTO, eyeing AIM relist and NASDAQ (Video)

Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
Aptamer

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform...
One Health Group

One Health Group shortlisted for two prestigious awards at the 30th anniversary AIM Awards

Sheffield-headquartered One Health Group plc (LON:OHGR), an independent provider of NHS-funded medical procedures, is delighted to announce that it has been shortlisted for two categories..
Roquefort Therapeutics

Roquefort Therapeutics plc plans transformational acquisition into clinical stage biotech company (LON:ROQ)

Roquefort Therapeutics has signed Heads of Terms to acquire 100% of Coiled Therapeutics, Inc. in a reverse takeover valued at £30 million, payable in shares. Coiled USA, a spin-out from A2A Pharmaceuticals, holds exclusive worldwide rights to AO-252, a first-in-class cancer therapy currently in Phase I trials in the United States...
Physicians Capital

Physicians turning professional insight into real estate advantage

Doctors are using their unique knowledge of healthcare operations to transform medical real estate into a source of stability and long-term independence...
Hutchmed

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...
Genus plc

Genus accelerates China joint venture with BCA to advance PRRS resistant pig

Genus plc has agreed updated terms with Beijing Capital Agribusiness to fast-track the formation of a porcine joint venture in China. The deal secures a US$160m cash payment, milestone income, and future royalties, while positioning PIC China to commercialise PRRS resistant pigs with stronger local backing...
Aptamer Group

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple